Literature DB >> 21336161

New insights into the pathogenesis of inflammatory bowel disease: transcription factors analysis in bioptic tissues from pediatric patients.

Maria Pierdomenico1, Laura Stronati, Manuela Costanzo, Roberta Vitali, Giovanni Di Nardo, Federica Nuti, Salvatore Oliva, Salvatore Cucchiara, Anna Negroni.   

Abstract

OBJECTIVES: Our work is aimed at identifying ex vivo new transcription factors, potentially involved in the pathogenesis of pediatric inflammatory bowel disease (IBD), by using a microarray approach. PATIENTS AND METHODS: Microarray, including 84 transcription factors, was performed in inflamed and uninflamed mucosal tissues of pediatric patients with Crohn disease (CD) and in healthy controls. Real-time polymerase chain reaction was used to confirm microarray results on a larger size of CD and patients with ulcerative colitis (UC). Protein expression was evaluated by Western blot assay.
RESULTS: Microarray assay showed 40 genes differentially regulated in the inflamed mucosa and 17 in the uninflamed mucosa of patients with CD as compared with controls. Real-time polymerase chain reaction analysis revealed 10 transcripts in CD and 4 in UC, selected among those with higher differences as compared with healthy controls, significantly overexpressed in the inflamed tissues of patients. Moreover, 4 transcripts in CD and 2 in UC were found significantly upregulated in the uninvolved tissue. A further investigation evidenced an increased protein expression of activating transcription factor 3 and hypoxia-inducible transcription factor-1α in patients with CD as well as in Caco2 cell line stimulated by cytokines and hypoxia.
CONCLUSIONS: The present study shows an evident upregulation of several transcription factors in the inflamed and uninflamed mucosa of children with IBD, suggesting that the inflammatory process is somehow activated at molecular levels even in the macroscopically normal mucosa of patients. A differential pattern of gene expression between CD and UC indicates distinct molecular mechanisms underlying the pathogenesis of 2 diseases. Finally, activating transcription factor 3 and hypoxia-inducible transcription factor-1α are proposed as new transcription factors potentially involved in the onset and maintenance of IBD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336161     DOI: 10.1097/MPG.0b013e3182034d08

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

Review 1.  Metabolic control of the Treg/Th17 axis.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

2.  Transcriptional factor ATF3 protects against colitis by regulating follicular helper T cells in Peyer's patches.

Authors:  Yingjiao Cao; Qiong Yang; Hui Deng; Jinyi Tang; Jiancong Hu; Huanliang Liu; Min Zhi; Linsen Ye; Bin Zou; Yongdong Liu; Lai Wei; Dmitry I Gabrilovich; Haikun Wang; Jie Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-12       Impact factor: 11.205

3.  MRI texture analysis parameters of contrast-enhanced T1-weighted images of Crohn's disease differ according to the presence or absence of histological markers of hypoxia and angiogenesis.

Authors:  Gauraang Bhatnagar; Jesica Makanyanga; Balaji Ganeshan; Ashley Groves; Manuel Rodriguez-Justo; Steve Halligan; Stuart A Taylor
Journal:  Abdom Radiol (NY)       Date:  2016-07

4.  The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel disease.

Authors:  Rikard Dammen; Rikard Damen; Martin Haugen; Bernhard Svejda; Daniele Alaimo; Oystein Brenna; Roswitha Pfragner; Bjorn I Gustafsson; Mark Kidd
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

5.  ATF3 Sustains IL-22-Induced STAT3 Phosphorylation to Maintain Mucosal Immunity Through Inhibiting Phosphatases.

Authors:  Doaa Glal; Janaki N Sudhakar; Hsueh-Han Lu; Ming-Che Liu; Hung-Yu Chiang; Yen-Chun Liu; Ching-Feng Cheng; Jr-Wen Shui
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.